Budding Alliance of Nanotechnology in RNA Interference Therapeutics

被引:6
|
作者
Kumawat, Akshant [1 ]
Dapse, Prachi [1 ]
Kumar, Narendra [1 ]
Mishra, Dinesh Kumar [2 ]
Maheshwari, Rahul [1 ]
Bhattacharya, Pallab [1 ]
Tekade, Rakesh Kumar [1 ]
机构
[1] Minist Chem & Fertilizers, Natl Inst Pharmaceut Educ & Res NIPER Ahmedabad, Inst Natl Importance Govt India, Dept Pharmaceut,Opposite Air Force Stn, Gandhinagar 382355, Gujarat, India
[2] SVKMs NMIMS, Sch Pharm & Technol Management, Shirpur 425405, India
关键词
Nanotechnology; RNA interference; siRNA; polymeric nanoparticles; metallic nanoparticles; nanotransformers; curdlan nanoparticles; SOLID LIPID NANOPARTICLES; IN-VIVO DELIVERY; SIRNA DELIVERY; GOLD NANOPARTICLES; CANCER-THERAPY; DRUG-DELIVERY; CHEMOTHERAPEUTIC-AGENTS; NONHUMAN-PRIMATES; GENE; CHALLENGES;
D O I
10.2174/1381612824666180807113948
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
RNA interference (RNAi), as a novel technique in which RNA molecules limit or silence the gene expression, is currently a hot research topic for producing novel therapeutic materials for challenging diseases. In the development of RNAi-based therapies, nanoscale particles, with a varying diameter along with facile modification methods that can mediate effective RNAi with targeting potential, are gaining wide interest. The nano-technology itself has tremendous potential in the field of healthcare, especially for the development of better pharmaceuticals. Nano-enabled delivery has shown great success in the delivery of RNAi based therapeutics to specific locations in the body. Especially, siRNAs show great potential for use in nucleic acid therapeutics because of their potent and specific RNAi-triggering activity. This review summarizes the advanced nanocarriers such as solid lipid nanoparticles, gold nanoparticles, silver nanoparticles, iron oxide nanoparticles, polymeric nanoparticles, nanotransformers and curdlan nanoparticles with special emphasis on various aspects of siRNA-based therapeutics.
引用
收藏
页码:2632 / 2643
页数:12
相关论文
共 50 条
  • [1] RNA Interference and Nanotechnology: A Promising Alliance for Next Generation Cancer Therapeutics
    Swaminathan, Guruprasadh
    Shigna, Aisha
    Kumar, Aviral
    Byroju, Vishnu Vardhan
    Durgempudi, Varsha Reddy
    Kumar, Lekha Dinesh
    FRONTIERS IN NANOTECHNOLOGY, 2021, 3
  • [2] Nanotechnology-based cancer therapeutics: View from the NCI Alliance for Nanotechnology in Cancer
    Grodzinski, Piotr
    Farrell, Dorothy
    Ptak, Krzysztof
    Panaro, Nicholas
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [3] The Development of RNA Interference Therapeutics
    Rossi, John J.
    NUCLEIC ACID THERAPEUTICS, 2011, 21 (06) : 371 - 372
  • [4] The Second International Conference on RNA Nanotechnology and Therapeutics
    Leontis, Neocles
    Sweeney, Blake
    Haque, Farzin
    Guo, Peixuan
    NANOMEDICINE, 2013, 8 (07) : 1051 - 1054
  • [5] Reconstitution of human RNA interference in budding yeast
    Suk, Kyoungho
    Choi, Jihye
    Suzuki, Yo
    Ozturk, Sedide B.
    Mellor, Joseph C.
    Wong, Koon Ho
    MacKay, Joanna L.
    Gregory, Richard I.
    Roth, Frederick P.
    NUCLEIC ACIDS RESEARCH, 2011, 39 (07) : E43 - U59
  • [6] RNA Interference as Therapeutics for Hepatocellular Carcinoma
    Xu, Chuanrui
    Lee, Susie A.
    Chen, Xin
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2011, 6 (01) : 106 - 115
  • [7] RNA interference therapeutics for cardiac regeneration
    Huntington, Josef
    Pachauri, Manendra
    Ali, Hashim
    Giacca, Mauro
    CURRENT OPINION IN GENETICS & DEVELOPMENT, 2021, 70 : 48 - 53
  • [8] RNA Interference as a New Tool in Therapeutics
    Matokanovic, Mirela
    Barisic, Karmela
    FOOD TECHNOLOGY AND BIOTECHNOLOGY, 2009, 47 (03) : 229 - 235
  • [9] RNA therapeutics: beyond RNA interference and antisense oligonucleotides
    Kole, Ryszard
    Krainer, Adrian R.
    Altman, Sidney
    NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (02) : 125 - 140
  • [10] RNA therapeutics: beyond RNA interference and antisense oligonucleotides
    Ryszard Kole
    Adrian R. Krainer
    Sidney Altman
    Nature Reviews Drug Discovery, 2012, 11 : 125 - 140